GREENVILLE,S.C., Nov. 10, 2020 \/PRNewswire\/ --Precision Genetics, a leader in the molecular laboratory and technology industries, announces today the launch of a new diagnostic test that simultaneously detects SARS-CoV-2 and Influenza A\/B strains in upper respiratory tract specimens. The test is available to health systems, providers, employers, and academic institutions alike.<\/p>\n
Precision Genetics' capabilities are essential for accurately detecting patients with COVID-19 and\/or the flu. \"By utilizing our high-complexity laboratory and testing methods, we can quickly and accurately distinguish between these viral infections,\" said Nate Wilbourne, founder and CEO of Precision Genetics. \"Our goal as a molecular laboratory is to ensure the highest levels of quality and efficiency to our clinical partners.\"<\/p>\n
The addition of this combination test comes just in time for the flu season. \"Most current testing looks only for COVID-19. As influenza infection rates rise, testing individuals only for Covid-19 is insufficient to distinguish between various viral illnesses of the upper respiratory tract,\" said John Wrangle, M.D,Chief Medical Officer of Precision Genetics. \"Knowing which virus a patient is infected with may help treating physicians, health professionals and health departments decide on the best course of treatment, surveillance and contact tracing.\"<\/p>\n
About Precision Genetics<\/p>\n
Precision Genetics is a high-complex molecular laboratory and technology company performing COVID-19 testing, COVID-19\/Flu combination testing and pharmacogenomics testing for employer safety and wellness, pre-surgical risk analysis and mental health.<\/p>\n
For more information on how your organization can benefit from our quick and reliable testing capabilities, please visit us at https:\/\/precisiongenetics.com<\/a>, send inquiries to [emailprotected], or call our team at (877) 843-6544 (ext 4).<\/p>\n SOURCE Precision Genetics<\/p>\n